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Abstract 
The parasitic protozoan Leishmania requires proteasomal, autophagic and lysosomal 
proteolytic pathways to enact the extensive cellular remodelling that occurs during its life 
cycle. The proteasome is essential for parasite proliferation, yet little is known about the 
requirement for ubiquitination/deubiquitination processes in growth and differentiation. 
Activity-based protein profiling of L. mexicana C12, C19 and C65 deubiquitinating cysteine 
peptidases (DUBs) revealed DUB activity remains relatively constant during differentiation of 
procyclic promastigote to amastigote. However, when life cycle phenotyping (bar-seq) was 
performed on a pool including 15 barcoded DUB null mutants created in promastigotes using 
CRISPR-Cas9, significant loss of fitness was observed during differentiation and intracellular 
infection. DUBs 4, 7, and 13 are required for successful transformation from metacyclic 
promastigote to amastigote and DUBs 3, 5, 6, 8, 10, 11 and 14 are required for normal 
amastigote proliferation in mice. DUBs 1, 2, 12 and 16 are essential for promastigote viability 
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and the essential role of DUB2 in establishing infection was demonstrated using DiCre 
inducible gene deletion in vitro and in vivo. DUB2 is found in the nucleus and interacts with 
nuclear proteins associated with transcription/chromatin dynamics, mRNA splicing and 
mRNA capping. DUB2 has broad linkage specificity, cleaving all the di-ubiquitin chains 
except for Lys27 and Met1. Our study demonstrates the crucial role that DUBs play in 
differentiation and intracellular survival of Leishmania and that amastigotes are exquisitely 
sensitive to disruption of ubiquitination homeostasis.  
 
Author Summary  
Leishmania parasites require a variety of protein degradation pathways to enable the 
parasite to transition through the various life cycle stages that occur in its insect and 
mammalian hosts. Several enzymes involved in protein degradation in Leishmania are 
known to be essential, including a multi-protein complex, the proteasome, but little is known 
about how proteins are targeted to the proteasome for degradation. Here, we analyse 
components of the deubiquitination pathway, including twenty cysteine peptidases (DUBs) 
that remove the posttranslational modifier ubiquitin from substrates tagged for proteasomal 
degradation. We used chemical probes to measure active enzymes in parasite lysates and 
genome engineering to create DUB gene deletion mutants. We identified some DUBs that 
are essential for parasite viability and some that are required for life cycle progression. We 
carried out a detailed analysis of the essential DUB2, which has broad deubiquitinase 
activity and is found in the nucleus. This enzyme interacts with nuclear proteins associated 
with transcription/chromatin dynamics, mRNA splicing and mRNA capping. This work 
demonstrates the important role that DUBs play in Leishmania in vivo infection and further 
validates DUBs as potential drug targets in this parasite. 
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Introduction 
Leishmaniasis is a vector-borne neglected tropical disease that causes serious public health 
problems in 98 tropical and sub-tropical countries and is responsible for 20,000  40,000 
deaths annually [1]. The disease spectrum varies from asymptomatic infection, through a 
disfiguring and debilitating mucocutaneous form to a visceral form that can be fatal. The 
causative agent of this disease is the obligate intracellular parasite of the genus Leishmania. 
The developmental process of Leishmania is closely linked with the ability of this parasite to 
survive and replicate in distinct environmental niches. The medical importance of one of 
these environmental niches is evident in the phagolysosomes of the infected host 
macrophages, where the Leishmania parasites differentiate from the motile promastigote to 
the non-motile amastigote and subsequently proliferate and establish an infection. The 
morphological and transcriptional changes that occur after differentiation of Leishmania 
promastigotes to amastigotes are well established [2], but little is known about the regulatory 
and operational processes that underpin this transition. Reversible post-translational 
modification (PTM) of proteins with chemical groups, such as phosphorylation, or other 
proteins, such as ubiquitination, are likely to be pivotal for successful life cycle progression 
[3-5] and intracellular parasitism. In addition, irreversible PTM such as proteolytic cleavage 
is important for the cellular remodeling that occurs during the life cycle of Leishmania and 
the commitment to differentiation [6-8], as well as in amastigote survival [9, 10]. 
Ubiquitination is an evolutionarily conserved post-translational modification involving a series 
of highly regulated enzymatic reactions resulting in attachment of ubiquitin to proteins in the 
cell [11]. Ubiquitination regulates vital cellular mechanisms including protein degradation 
through the ubiquitin-proteasome system (UPS), autophagy, DNA repair and protein 
trafficking. For the covalent attachment of ubiquitin to target protein or other ubiquitin, three 
types of enzymes are required to act sequentially: E1 ubiquitin-activating enzyme, E2 
ubiquitin-conjugating enzyme and an E3 ubiquitin ligase [11]. This system is reversible and 
deubiquitinase enzymes (DUBs) are responsible for the removal of ubiquitin from the target 
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protein, providing an additional level of regulation of the ubiquitination pathway [12]. The 
number of DUBs varies from organism to organism. For example, around 100 DUBs have 
been discovered in humans but only 20 DUBs have been found in Saccharomyces 
cerevisiae [13]. In general, DUBs can be divided into seven distinct structural families [14]: 
ubiquitin-specific proteases (USPs, family C19), C-terminal hydrolyses (UCHs, family C12), 
ovarian tumor proteases (OTUs, family C65), JAB1/MPN/MOV34 metalloenzymes 
(JAMM/MPN+, family M67), Josephins, family C86, MINDY, family C115 [15] and the newly 
identified ZUFSP (zinc finger with UFM1-specific peptidase domain protein), family C78 [13, 
15]. Here we characterise DUBs of Leishmania and describe a bar-seq CRISPR-Cas9 
genome editing strategy that was used to evaluate the requirement for DUB activity in the 
Leishmania life cycle. Our data demonstrate that the broad and diverse mechanisms used 
by DUBs are required for successful Leishmania life cycle progression. 
 
Results 
Leishmania deubiquitinase cysteine peptidase gene family 
We searched the genome of L. mexicana and identified 20 DUBs belonging to the C12, C19 
and C65 families (S1 Table). Nineteen of these 20 DUBs are conserved in the closely 
related trypanosomatid Trypanosoma brucei, with only the C19 family DUB18 being absent. 
Domain analysis using InterPro [16] confirmed the presence of the expected DUB peptidase 
domains. Furthermore, several other domains including UBA [17], zinc finger UBP-type [18], 
WD40, exonuclease RNase and PAN2 domains were also identified (Fig 1A). 
 
Fig 1. Leishmania DUBs domain analysis and phylogenetic tree. (A) Domain analysis of 
20 predicted cysteine peptidase DUBs. InterPro was used to analyse protein sequences. 
Identified domains, including their InterPro entry code, are shown. (B) Phylogenetic tree for 
the deubiquitinase domains of L. mexicana and H. sapiens DUBs. UBA; ubiquitin 
associated, DUSP; domain present in ubiquitin-specific proteases, OTU; ovarian tumour, 
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UCH; ubiquitin C-terminal hydrolase, PAN; poly(A)-specific nuclease, USP; ubiquitin-specific 
protease, UCH; Ubiquitin carboxyl-terminal hydrolase, MINDY; Motif interacting with 
ubiquitin-containing novel DUB family, JOS; Josephin domain-containing, JAMM; 
Jab1/Mov34/Mpr1, ZUP; Zinc finger-containing ubiquitin peptidase. 
 
A phylogenetic tree of L. mexicana and Homo sapiens DUBs revealed the clustering of 
Leishmania DUBs into human DUB families. DUB15 and DUB16 clustered with mammalian 
C12 UCH DUBs and DUB17 with mammalian C65 OTU as expected (Fig. 1B). USP (C19) 
DUBs are the largest class of DUBs in humans (~60 members) and also in L. mexicana (17 
members). Most of the USPs include domains in addition to their C19 catalytic domain. The 
C19 DUBs have limited sequence conservation, restricted to the catalytic domain which 
consists of an active catalytic triad including Cys, His and Asp or Asn residues. The rest of 
the protein sequence is highly diverse among the USPs and it is believed that this sequence 
diversity is crucial for the substrate recognition through interaction with other proteins. 
 
Sequence alignments revealed that all of the DUBs contained the catalytic triad except for 
DUB13, which has an Asn in place of the consensus His (S1 Fig). DUB13 is the orthologue 
of human USP52, also known as PAN2, a subunit of the deadenylation complex [19].  PAN2 
lacks some of the catalytic triad residues in the DUB domain that are thought to be important 
for DUB activity including the active Cys [20], yet PAN2 is able to cleave K6-, K11-, K48-, 
K63-, and M1-linked ubiquitin chains, suggesting that specific post-translational 
modifications or protein folding could rearrange its active site to form a new active centre 
[21]. 
 
Leishmania DUBs required for life cycle transition 
The fluorescent activity-based probe (ABP) Cy5UbPRG, previously developed for its ability 
to react with active DUBs [22], identified active DUBs in the lysate of L. mexicana 
promastigotes. In-gel fluorescence (Cy5) showed the presence of several DUBs in the range 
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of 30-160 kDa (Fig 2A), the size expected taking into account the covalent attachment of the 
9 kDa Cy5UbPRG probe (S1 Table). The activity of DUBs detected with the ABP was similar 
in promastigotes, axenic amastigotes and lesion-derived amastigotes and during 
differentiation from amastigotes to promastigotes (Fig 2B). UbPRG was then attached to 
Sepharose beads and used to affinity purify proteins from an L. mexicana promastigote cell 
lysate, and mass spectrometry used to confirm DUB identity. Six DUBs (DUB2, DUB15, 
DUB16, DUB17, DUB18, and DUB19) were successfully identified only in the UbPRG 
sample and not in the control sample, indicating that the warhead can successfully react with 
cysteine peptidase DUBs (Fig 2C and S2A Table). Twenty other proteins specifically 
identified in the UbPRG sample are likely to be proteins that are DUB substrates (such as 
polyubiquitin, LmxM.09.0891), form complexes with DUBs, or react directly with the PRG 
warhead. 
 
Fig 2. Validation of DUB null mutants. (A) DUB activity in L. mexicana promastigote cell 
lysates was profiled using Cy5UbPRG. Proteins were resolved by SDS-PAGE and in-gel 
fluorescence (Cy5) was captured using a Typhoon imager. Black arrows represent the 
higher intensity activities. (B) DUB activity profiled using Cy5UbPRG in log phase 
promastigotes (PRO Log), stationary phase promastigotes (PRO Stat), axenic amastigotes 
(AXA) grown for 24, 48 and 72 h after differentiation from stationary phase promastigotes, 
lesion-derived amastigotes (AMA) and promastigotes 24, 48 and 72 h after differentiation 
from AMA. (C) Summary of null mutant generation and isolation of DUBs by affinity 
purification. Green, successful; red, not successful. F., facilitated; Spe., spectrometry. (D) 
Example of diagnostic PCRs performed to confirm a null mutant for a non-essential gene 
(ǻdub7), a heterozygote for an essential gene (ǻdub2) and the generation of a facilitated 
null mutant (ǻdub2 [DUB2]). (E) DUB activity profiling of lysate extracted from null mutant 
lines of log-phase L. mexicana promastigotes. Arrowheads represent the absence of an 
active DUB compared to the Cas9 T7 parental cell line. (F) DUB activity profiling of lysate 
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extracted from facilitated null mutant lines of log-phase L. mexicana promastigotes. The 
arrow heads represent the DUB expressed from the episome. 
 
To assess whether the 20 DUBs were dispensable for growth of L. mexicana promastigotes 
each gene was targeted for deletion using CRISPR-Cas9  [23] with two barcoded antibiotic 
resistance cassettes to attempt to replace both allelic copies of each DUB (Fig 2C). In the 
first round of transfection into the parental L. mex Cas9 T7 line, two independent null mutant 
lines were generated for 13 DUBs (ǻdub3, ǻdub5, ǻdub7, ǻdub8, ǻdub9, ǻdub10, ǻdub11, 
ǻdub14, ǻdub15, ǻdub17, ǻdub18, ǻdub19, ǻdub20) and validated using PCR to detect 
correct integration of the resistance cassettes and removal of the open reading frame (Fig 
2D, S2 Fig and S3 Table). After further transfections, another 3 null mutants were isolated 
(ǻdub4, ǻdub6 and ǻdub13), making a total of 16. For four DUBs, DUB1, DUB2, DUB12 
and DUB16, null mutants could not be generated. 
 
To identify the DUB activities detected in promastigotes (Fig 2A), cell lysates for the DUB 
null mutants were probed with the Cy5UbPRG ABP (Fig 2E, S3 Fig), with the expectation 
that the absence of a band of activity in comparison to the L. mexicana Cas9 T7 would 
represent the DUB that had been deleted. This allowed us to identify 5 active DUBs close to 
their expected sizes; DUB6 (133 kDa), DUB9 (155 kDa), DUB15 (34 kDa), DUB17 (30 kDa) 
and DUB18 (102 kDa). The fact that DUB15, DUB16, DUB17, DUB18, and DUB19 had been 
affinity purified with the UbPRG probe shows that these DUBs are active in the promastigote 
stage. A similar-sized DUB activity present in L. mexicana Cas9 T7 was absent in 
promastigotes of both ǻdub13 and ǻdub19, but we were unable to identify the DUB. Of note, 
PAN2, the human orthologue of DUB13, does not appear to bind the Cy5UbPRG probe [24], 
as it lacks key catalytic residues including the active Cys. This may also be true for L. 
mexicana DUB13. 
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To investigate further, promastigote cell lines were differentiated to amastigotes and probed 
with the ABP. This allowed DUB8 (172kDa) and DUB19 (148kDa) to be identified by 
comparing wild type and ǻdub8 and ǻdub19 (S3B Fig). Several null mutant DUB cell lines 
did not show any depletion of activity with the Cy5UbPRG profiling in either promastigotes or 
amastigotes, suggesting that those DUBs are not expressed, not active or are below 
detection limits of the ABP in the promastigote stage under the environmental conditions 
tested. Alternatively, the DUBs may not bind the ABP.  
 
It was not possible to isolate null mutant clones for DUB1, DUB2, DUB12 and DUB16, 
possibly because those DUBs are essential in promastigotes (Fig 2C). In three instances 
(DUB1, DUB2 and DUB12), correct integration of the drug resistance cassettes was 
observed, but the parasites retained a wild type copy of the gene, indicating that the genes 
are essential (S2 Fig). For DUB16, no populations could be recovered after the 
transfections. To provide further evidence that the genes are essential and to discount the 
possibility that the lack of gene deletion was a technical failure, facilitated null mutants were 
generated for the four DUB genes. Initially, the parental Cas9 T7 cell line was transfected 
with a plasmid expressing the DUB, thereafter the two alleles in the genomic locus were 
deleted successfully using CRISPR, two independent populations isolated, and the expected 
gene editing confirmed by diagnostic PCR (Fig 2D and S2 Fig). The Cy5UbPRG ABP was 
used to identify the over-expressed and active DUBs in the L. mexicana Cas9 T7 [DUB] cell 
lines (Fig 2F), where an increase in specific activities were detected in the over-expression 
lines compared to the parental line (Fig 2F, arrow heads). For DUB2 and DUB16 the 
expected sizes of 81 and 25 kDa were detected respectively, once the ~9 kDa mass of the 
ABP had been taken into account.  In contrast, both DUB1 (expected size 65 kDa, observed 
size 40 kDa) and DUB12 (expected size 89 kDa, observed sizes 45 and 50 kDa) are smaller 
than expected and seem likely to be proteolytically processed in the cell (Fig 2F). 
 
Bar-seq reveals the importance of DUBs in the L. mexicana life cycle 
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To assess the ability of the DUB null mutants to transition through the parasite life cycle, bar-
seq analysis, a method that involves the parallel phenotyping of pools of mutants using high-
throughput DNA sequencing, was carried out [25]. Our 58 barcoded null mutants 
representing 16 DUBs, 13 other peptidases, 25 other ubiquitination system genes and 4 
protein kinases (S4 Table) were prepared in equal proportions in 6 replicate promastigote 
(PRO) pools. The pools were grown for 7 d before samples were collected and either 
induced to form axenic amastigotes (AXA) or used to purify metacyclic stage promastigotes 
(META). Purified metacyclic promastigotes were used to infect macrophages (inMAC) in 
vitro or mice via footpad (FP) injection. At various time points, DNA samples were prepared 
from the pool for amplification of the barcodes by PCR and quantitative analysis via next 
generation sequencing (Fig 3A, S4 Table). 
 
Fig 3. Life cycle phenotyping of DUB null mutants by bar-seq. Fifty-eight null mutants 
were pooled (n = 6) as promastigotes and grown to stationary phase before being induced to 
differentiate to axenic amastigotes in vitro or used for metacyclic purification and subsequent 
infection of macrophages or mice. At the time points indicated in (A), DNA samples were 
extracted for barcode amplification by PCR and quantitative analysis by next generation 
sequencing. Average proportional representation of null mutant-specific barcodes at each 
experimental stage is displayed in the heat maps for (B) axenic amastigote, (C) macrophage 
infection and (D) mouse infection experiments. Samples included represent promastigote 
time-point zero (PRO 0 h), early-log phase (PRO 24 h), mid-log phase (PRO 48 h), late-log 
phase (PRO 72 h), stationary phase (PRO 168 h), early axenic amastigote differentiation 
(AXA 24 h), post-axenic amastigote differentiation (AXA 120 h), purified metacyclics (MET), 
early macrophage infection (inMAC 12 h), late macrophage infection (inMAC72 h), 3 week 
footpad mouse infection (FP 3) and 6 week footpad mouse infection (FP 6). Separately, 
individual null mutant lines were grown to stationary phase and induced to differentiate into 
axenic amastigotes. Cell viability was measured at the stages indicated in (E) using 
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resazurin (added 24 h prior to each measurement). A transformation step back to 
promastigotes was included. Measurements of cell viability were calculated relative to the 
wild-type at each experimental stage. The data are an average of two independent 
experiments. 
 
In order to analyse fitness, defined as the reproductive capacity of a given population in a 
given environment the number of reads for each barcode was first divided by the total 
number of reads for expected barcodes at each experimental stage. Next, data were 
averaged across the 6 replicates and the barcodes matched back to their respective null 
mutant lines. Changes in the average proportional representation of these lines were then 
used to infer changes in fitness. Importantly, because of the potential for the cumulative loss 
of null mutant lines during the experiment, statistical tests to investigate loss of fitness were 
only applied between adjacent time points. This ensured that the experimental period linked 
with a particular viability defect could be identified. Additionally, because of the higher 
likelihood that null mutant lines would exhibit decreased, rather than increased, fitness 
during the experiment (leading to an overall increase in the proportional representation of 
remaining null mutant lines), increases in fitness could not be confidently reported. 
Consequently, our analysis focuses only on deficiencies in life cycle progression. 
 
Barcodes were detected for all null mutant lines at time point zero, however, very few reads 
were found for ǻdub18 (most likely due to experimental error), leading this null mutant line to 
be excluded from the analysis. Decreased fitness was observed between adjacent 
promastigote stages (PRO 0 h-PRO 168 h) for a number of null mutant lines, with ǻdub8, 
ǻdub9 and ǻdub13 in particular showing reduced fitness at two promastigote time points 
(unpaired t-tests with Holm- ídák correction for multiple comparisons, <0.05). None of the 
mutants had significantly decreased fitness between the 168 h and metacyclic (META) 
samples, however, strong loss of fitness was common upon entering the amastigote life 
14 
 
cycles stages (AXA 24 h onwards, inMAC 12 h onwards and FP 3 weeks onwards, Fig 3B-D 
respectively). Strong defects in both axenic amastigote differentiation and macrophage 
infection were observed for ǻdub4, ǻdub7 and ǻdub13 (100-fold, >7-fold and >50-fold 
decreases in fitness respectively). Additionally, decreased fitness was observed for ǻdub5, 
ǻdub8, ǻdub9, ǻdub10 and ǻdub11 between the AXA 24 h and AXA 120h stages and for 
ǻdub6, ǻdub11 and ǻdub17 between the MET and inMAC 12 h stages. Consistent with their 
phenotypes in axenic amastigotes, ǻdub4, ǻdub7 and ǻdub13 showed severe reductions (to 
zero) in fitness during mouse infection. Additional defects of 20-fold or more reduction in 
fitness were also seen for ǻdub3, ǻdub5, ǻdub6, ǻdub8, ǻdub10, ǻdub11 and ǻdub14. 
While many examples of loss of fitness in mouse infection were observed for DUBs and 
other ubiquitination system mutants studied (S4 Table), loss of fitness phenotypes were less 
common for other peptidase mutants in the screen, including members of the calpain (C2), 
SUMO-specific peptidase (C97) and D-alanyl-glycyl endopeptidase (C51) families [26]. 
 
To demonstrate the validity of the phenotypes observed in the bar-seq screen, null mutants 
were also analysed individually at 24, 72 and 144 h after induction of amastigote 
differentiation and 48 h after transformation of axenic amastigotes back to promastigotes 
using resazurin, an oxidation-reduction indicator that reports on cell activity. The data from 
this experiment match well with the phenotypes observed in the AXA bar-seq data (Fig 3E). 
An exception to this is ǻdub9 which is well represented throughout the bar-seq experiment 
but loses viability at 72 h in the cellular assay, perhaps indicating the persistence of ǻdub9 
beyond 72 h but in a metabolically inactive state. The viability data also support more 
unusual phenotypes. For example, ǻdub6 is still well represented at the AXA 24 h and 120 h 
stages of the bar-seq experiment but less so at the inMAC 12 h stage. This is supported by 
data from the viability assay showing that ǻdub6 is viable throughout amastigote 
differentiation. Based on this finding, one could hypothesise that DUB6 may contribute to 
part of the infection process such as parasite entry into macrophages or survival in the 
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phagolysosomes. Overall, the phenotypes observed in the pooled context of the bar-seq 
experiment reflect well the individual phenotyping of the viability assay. To further validate 
how these null mutants behave during amastigote differentiation, a western blot against 
HASPB, a marker for amastigotes [27], was performed. ǻdub4, ǻdub7, ǻdub9 and ǻdub13 
showed very low or no expression of HASPB 120 h after the initiation of differentiation (S3 
Fig). These results further demonstrate the inability of ǻdub4, ǻdub7, ǻdub9, and ǻdub13 to 
differentiate into amastigotes (first shown in Fig 3E).  
 
DUB2 activity is essential for L. mexicana 
L. mexicana DUB2 is one of the four essential DUBs identified in the CRISPR-Cas9 screen 
and is classified as a member of the USP family, closely related to mammalian USP5, 
USP13 and USP1 (Fig 1B). DUB2 domain analysis suggested the presence of a peptidase 
C19, ubiquitin carboxyl-terminal hydrolase domain, a UBA (ubiquitin-associated domain and 
a Zinc finger UBP-type (Znf_UBP)) (Fig 1A). The UBA domain found in the C-terminal end of 
DUB2 is present in many proteins associated with the ubiquitin system, and it is responsible 
for the binding of ubiquitinated substrates [28]. The Zinc finger domain is found only in a 
minor subfamily of USP DUBs including the mammalian USP5, USP13 and USP39, 
regulators of deubiquitination [18].  
 
A modified version of the inducible DiCre system [29] was applied to L. mexicana DUB2 to 
investigate its function in promastigotes. The first allele of DUB2 was replaced with a DUB2 
flanked by LoxP sites (ǻdub2::DUB2FLOX/DUB2, called DUB2+/+FLOX). Subsequently, the 
second allele of DUB2 was replaced with a HYG resistance cassette 
(ǻdub2::HYG/ǻdub2::DUB2FLOX, called DUB2-/+FLOX). The expected genetic modifications for 
several clones were confirmed by PCR (S5A,B Fig). Excision of DUB2 in DUB2+/+FLOX and 
DUB2-/+FLOX logarithmic phase promastigotes was confirmed by the PCR amplification of a 
1.3 kb DNA fragment in only those cells treated with 100 nM rapamycin (Fig 4A). A 
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pronounced defect in cell growth was observed in the rapamycin treated DUB2-/+FLOX cell line 
in comparison to DUB2+/+FLOX or untreated controls, indicating that deletion of both DUB2 
alleles is required to elicit a growth phenotype (Fig 4B).  The Cy5UbPRG ABP demonstrated 
that the activity of DUB2 sharply decreased in the induced DUB2-/+FLOX line, but not in 
DUB2+/+FLOX or WT (Fig 4C). For further analysis, the in-gel fluorescence band intensity was 
quantified for the DUB2-/+FLOX line, showing one band (band 9) had a 70% depletion after 
rapamycin induction (Fig 4D). Band 9 is the same size as that observed in the episomal 
over-expression of DUB2 (Fig 2E) and correlates with the predicted mass of DUB2 protein 
covalently bound to the ABP (~100 kDa). A second unidentified DUB, labelled Unk 4, had a 
slight increase in activity after depletion of DUB2 in the DUB2-/+flox line (Fig 4C, D). Loss of 
DUB2 may cause a compensatory change in activity for this DUB.  
 
Fig 4. Conditional deletion of DUB2. (A) (Top) Schematic representation of the loxP-
flanked DUB2 allele before and after rapamycin-induced recombination by DiCre. Arrows 
represent the primers used for the PCR to check for the successful excision of DUB2. 
(Bottom) PCR amplification of DUB2-+/+FLOX and DUB2-/+FLOX +/- 100 nM RAP for 48 hours 
was conducted and the resulting amplicons resolved on 1% agarose gel stain with SYBR 
safe. (B) DUB2+/+FLOX and DUB2-/+FLOX promastigotes were seeded at a density of 1 × 105 
cells mLí1 and grown in the absence or presence (-/+) of 100 nM RAP for 48 h. Cells were 
diluted to 1 × 105 cells mLí1 and allowed to grow in the presence or absence of 100 nM RAP 
for 4 d. Cell density was determined by counting at 24 h intervals and mean ± SD of triplicate 
values were plotted. The data were analysed in Prism software, and an unpaired t-test 
performed to indicate the significance (n=5) between different time points, comparing treated 
with RAP to untreated samples. Error bars show the standard deviation of the mean. ****p < 
0.0001. (C) DUBs visualised by in-gel fluorescence analysis after separation by SDS PAGE. 
Samples were lysed, and 25 ȝg of lysate was incubated with the probe for 30 min. The 
positions of the different DUBs are indicated. (D) Fold difference of the DUB activity 
comparing DUB2 induced/DUB2 non-induced of the DUB2-/+FLOX, data from (C). Band 
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intensities were quantified by densitometry using GelAnalyzer 19.1 software. Each band is 
represented as a percentage of the total activity. The percentages for each band for the 
induced sample were divided by the non-induced to determine the fold difference. The data 
were then analysed in Prism software. Each column represents the mean of data from three 
independent experiments. Error bars show the standard deviation of the mean. Blue 
represents an increase of more than 1.3-fold whereas red represents a difference of less 
than 0.7-fold. (E) Percentage of surviving clones of DUB2+/+FLOX, DUB2-/+FLOX clone 4, DUB2-
/+FLOX clone 6, DUB2-/+FLOX [DUB2] and DUB2-/+FLOX [DUB2C312A] promastigotes after RAP 
induction. The cell lines were incubated with or without RAP for 48 hours. Next, cells were 
counted and cloned into 96 well plates. After 4 weeks, plates were checked for surviving 
parasites. The data were then collected and analysed in Prism software. 100% represents 
the highest number of surviving parasites that were collected from an individual experiment 
in the absence of RAP. Each column represents the mean of data from three independent 
experiments. Error bars show the standard deviation of the mean. ****p < 0.0001. (F) DUBs 
were visualised by in-gel fluorescence analysis after separation by SDS-PAGE. Samples 
were lysed and 25 ȝg of lysate was incubated with the probe for 30 min. Lysate was 
collected from DUB2-/+FLOX, DUB2-/+FLOX [DUB2] and DUB2-/+FLOX [DUB2C312A] promastigotes 
grown in the presence of 10 ȝg ȝLí1  of G418. (G) Western blotting analysis with anti-
TbDUB2 (1;1,000) and anti-LmOPB (1:20,000) (loading control) antibodies on protein 
extracted from DUB2-/+FLOX, DUB2-/+FLOX [DUB2] and DUB2-/+FLOX [DUB2C312A] promastigotes 
grown in the presence of 10 ȝg ȝLí1 of G418. 
 
To confirm that the depletion of DUB2 leads to cell death a clonogenic assay was performed 
on DUB2+/+FLOX and DUB2-/+FLOX promastigotes following treatment with rapamycin or DMSO 
for 48 h. A >90% decrease in numbers of clones surviving for both DUB2-/+FLOX clones was 
observed for cells treated with rapamycin, whilst there was no difference in the number of 
clones surviving in the DUB2+/+FLOX line, despite the presence of rapamycin (Fig 4E). These 
data confirm that the loss of DUB2 leads to death of promastigotes and that one allele of 
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DUB2 can sustain growth. Finally, diagnostic PCR confirmed the presence of DUB2 in 
DUB2-/+FLOX cells that survived rapamycin treatment, showing that if DUB2 is deleted, the 
cells were non-viable (S5B Fig). In support of these observations a significant increase in 
cell death was observed using propidium iodide staining after induction (S5C Fig).  
 
Alignment of the C19 domain of DUB2 with other DUBs allowed the identification of C312 as 
the likely active site Cys. A point mutation was introduced into DUB2 in a pNUS plasmid to 
change the encoded Cys 312 to alanine, which would result in abolishment of DUB2 activity. 
pNUS-DUB2 and pNUS-DUB2C312A plasmids were transfected into DUB2-/+FLOX and an ABP 
assay with Cy5UbPRG used to confirm an increase of DUB2 activity in DUB2-/+FLOX [DUB2] 
but not DUB2-/+FLOX [DUB2C312A] (Fig 4F). Over-expression of DUB2 was confirmed in both 
DUB2-/+FLOX [DUB2] and DUB2-/+FLOX [DUB2C312A] cell lines by western blot using an antibody 
raised against T. brucei DUB2; this cross-reacts with L. mexicana DUB2 (Fig 4G). These 
data confirm that C312 is the active site Cys and is required for DUB2 activity. The loss of 
the DUB2 following rapamycin treatment resulted in a 90% decrease in the number of DUB2-
/+FLOX [DUB2C312A] clones in comparison to DUB2-/+FLOX [DUB2] (Fig 4E); indeed, expression 
of DUB2 in the DUB2-/+FLOX line resulted in full complementation of the cell death phenotype. 
Taken together, these experiments strongly support that the deubiquitinase activity of DUB2 
is required for the survival of L. mexicana promastigotes. 
 
The DUB2-/+FLOX line was also used to examine if DUB2 is essential for infection and survival 
in BALB/c mice.  Mid-log phase WT and DUB2-/+FLOX were grown in the presence or absence 
of rapamycin for 72 h and then inoculated into BALB/c mice. Efficient excision of DUB2 was 
confirmed by PCR (Fig 5A). The mice infected with the rapamycin-treated WT or non-treated 
DUB2-/+FLOX showed a steady growth in footpad size whereas rapamycin-treated mice DUB2-
/+FLOX did not develop a footpad lesion (Fig 5B), had 100-fold less parasites than non-treated 
in the footpad and could not be detected in the popliteal draining lymph nodes (Fig 5C). The 
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presence of a small number of parasites in the footpad of treated mice might be due to the 
presence of a subpopulation of cells that retained the floxed DUB2. This was supported by 
the finding that DUB2 could be detected by PCR in cells isolated from treated DUB2-/+FLOX 
lesions (Fig 5D). In summary, DUB2 is required either for the establishment and/or 
maintenance of an infection in mice. 
 
Fig 5. In vivo characterisation of DUB2. (A) PCR amplification of the floxed DUB2 locus of 
DUB2-/+FLOX of 4 x 106 cells mL-1 log phase promastigotes after incubation in the presence (+) 
or absence (-) of 1 ȝM RAP for 72 h. The resulting amplicons were resolved in 1% agarose 
gel stain by SYBR safe. Schematic representation of the primers used for the PCR, as well 
as the expected fragments (4.5 kb, 1.3 kb), are shown in Fig. 4a. (B) Mice were infected in 
the footpad with 2 x 106 WT+RAP, DUB2-/+FLOX and DUB2-/+FLOX+RAP promastigotes and 
footpad size was recorded by weekly caliper measurement. Data were analysed in Prism 
software. Data shown represent the mean footpad size and SD from groups of five mice. (C) 
Parasite burden. Mice were sacrificed after 4 weeks, and parasite loads in footpad and 
popliteal lymph node were determined by limiting dilution. Statistical analyses were 
performed in Prism software using the paired t-test. (D) PCR amplification to check DUB2 
excision of the samples collected from the mice which were infected with the DUB2-/+FLOX 
+RAP. The resulting amplicons were resolved in 1% agarose gel stained with SYBR safe. 
Schematic representation of the primers used for the PCR, as well as the expected 
fragments (5.6 kb, 1.3 kb), are shown in Fig 4A. 
 
The DUB2 interactome 
To gain more insight into the function of DUB2, the DUB2 interactome was investigated. The 
expression of active N-terminally tagged 3 x myc mNeo DUB2 was confirmed with the ABP 
and Western blotting (S6 Fig). DUB2 and an N-terminally tagged 3 x myc mNeo RDK2 
control were immune-precipitated from L. mexicana promastigote cell lysates and proteins 
identified by mass spectrometry. Parasites were cross-linked with dithiobis(succinimidyl 
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propionate) to enable transient interactors to be captured, including possible substrates of 
DUB2. In the DUB2 samples, a total of 1269 protein groups were identified across 3 
independent replicates, of these 818 were commonly identified in all three DUB2 replicates. 
Data were processed with an interaction scoring algorithm SAINTq to provide a score on the 
probability of a true interaction with DUB2. This analysis produced a list of 110 high 
confidence DUB2 interactors at <1% FDR (Fig 6, S5 Table). The list includes a number of 
proteins involved in ubiquitination, including polyubiquitin, three putative E2 ubiquitin-
conjugating enzymes (LmxM.34.1300, LmxM.04.0680, LmxM.13.1580) and an ubiquitin-like 
modifier peptidase (LmxM.32.2260). Among the most enriched proteins was CYC12 
(LmxM.36.5640), an L-type cyclin involved in spliced leader trans-splicing of pre-mRNA [30]. 
Other proteins involved in mRNA splicing were also enriched including SmD2, U5 snRNP 
and snRNP-B. Three members of the cleavage and polyadenylation specificity factor 
complex (CPSF) and a cleavage stimulation factor co-purified, suggesting a role for DUB2 in 
the processing of mRNA. Proteins involved in mRNA capping, CBP110 and CGM1, were 
also strongly enriched with DUB2. In addition, 19 of the interactors are either annotated as 
RNA binding or known to have a role in RNA metabolism. A smaller number of DUB2 
interactors are implicated in transcription, however, this group includes the top enriched 
interactor NIF3. Interestingly, among this group of proteins involved in 
transcription/chromatin dynamics is Nucleosome Assembly Protein, NAP, which was 
enriched 27-fold. In humans, NAP1 is a histone chaperone and plays an important role in 
nucleosome assembly/disassembly by binding to free H2A/H2B dimers [31]. Cycles of 
ubiquitination and de-ubiquitination of H2B are well known to play an important role in 
nucleosome dynamics during transcription and DNA replication. Several proteins with key 
roles in DNA replication were also identified as DUB2 interactors, such as PCNA, DNA 
polymerase delta and subunits of replication factor A and C. In other organisms, multiple 
components of the DNA replication machinery are ubiquitinated, in particular, ubiquitination 
of PCNA is critical for recruitment of DNA polymerases [32]. The identification of VPS4 [33] 
and a dynamin-1 like protein suggest involvement of DUB2 in endosomal trafficking. Finally, 
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3 protein kinases were co-enriched, including a mitogen activated protein kinase kinase 
(MKK1). This suggests a mechanism of DUB2 regulation, therefore mass spectrometry data 
were searched for phosphorylation sites revealing that DUB2 is phosphorylated on a serine 
in the region 586-589. A ubiquitination site in DUB2, K681, was also identified suggesting 
that DUB2 itself may be regulated by the ubiquitination pathway (S6 Table). Overall, the 
multiple interactions of DUB2 with splicing factors, proteins involved in mRNA capping and 
factors regulating chromatin dynamics/transcription, place DUB2 near actively transcribing 
genes. 
 
Fig 6. DUB2 interactome. Summary of detected DUB2 interactions. Myc-DUB2 was 
immuno-precipitated from promastigotes and binding partners identified by label free 
quantitative mass spectrometry. Interaction data were analysed with SAINTq, high 
confidence interactors (<1% FDR) were selected and are shaded according to fold 
enrichment against a control immuno-precipitation. Detected ubiquitination sites (Ub) and 
phosphorylation (P) are shown. Interactors are grouped according to the annotated function. 
A total of 110 high confidence interactors were identified. Non-annotated or ribosomal 
proteins have been omitted for clarity. 
 
DUB2 has deubiquitinating activity 
To explore the function of DUB2 in more detail, recombinant enzyme (DUB2) and a 
catalytically inactive form (DUB2C312A) were expressed and purified using a baculovirus 
insect cell expression system (S7 Fig). DUB2, but not DUB2C312A recombinant protein 
reacted with the Cy5UbPRG probe (Fig 7A) and 85% of the recombinant DUB2 reacted with 
the probe (Fig 7B). DUB2 linkage specificity against all eight types of human di-ubiquitin was 
then investigated over 30 min at a constant enzyme and substrate concentration. At 0.02 nM 
DUB2 had a preference for cleavage at Lys-11, Lys-29, Lys-33 and Lys-63, but at 2 nM 
DUB2 cleaved all linkages except Lys-27 (Fig 7C). Finally, DUB2, but not DUB2C312A 
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recombinant protein had activity towards Ub-AMC substrate with a kcat of 0.049 s
-1 and a Km 
of 14.9 x 10-6 M (Fig 7D).  
 
 
Fig 7. In vitro characterization of DUB2 recombinant protein. (A) 500 ng of purified 
DUB2 and DUB2C312A were incubated with or without 1.2 ȝg of Cy5UbPRG for 30 min. 
Samples were analysed by SDS-PAGE gel electrophoresis with in-gel fluorescence (Cy5). 
The gel was stained in InstantBlue protein stain. The yellow arrowhead indicates DUB2 and 
the red arrowhead shows DUB2 in complex with the Cy5UbPRG probe. (B) The stained gel 
in (A) was analysed using GelAnalyzer 19.1 software to determine the band intensity for 
DUB2 and DUB2 in complex with the ABP. Data were then collected and analysed to 
determine the ratio between the active and inactive form of DUB2 in Prism software. (C) 
Different di-ubiquitin linkage types were incubated with recombinant DUB2 (0.02 nM or 2 
nM) for the times indicated and proteins resolved by SDS-PAGE gel and stained with 
InstantBlue Protein Stain. (D) Michaelis-Menten kinetic analysis for DUB2 hydrolysis of Ub-
AMC. Error bars represent s.d. from the mean. Reactions containing 400 nM DUB2 were 
initiated by the addition of Ub-AMC at final concentrations between 0.25 ȝM and 32 ȝM. 
Assays were performed in triplicate for three independent experiments. Initial rates were 
determined by calculating the gradient of a linear regression of the product concentration 
against time (from 0-400 sec). 
 
Discussion 
Recent studies showed the potential for proteasome inhibition as a treatment for three 
diseases caused by trypanosomatid parasitic protozoa, including leishmaniasis [9, 10]. The 
proteasome is dependent on the ubiquitination pathway to identify substrates for degradation 
and a search of the Leishmania genome reveals a range of E1, E2 and E3 ligases, as well 
as a number of DUBs [34]. Nevertheless, there have been no extensive studies exploring 
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the role and essentiality of Leishmania DUBs through the complex life cycle of the parasite. 
Our bioinformatic analysis identified 20 DUBs belonging to the C12, C19 and C65 peptidase 
families, suggesting an extensive deubiquitinating system in L. mexicana, comparable in 
size to Saccharomyces cerevisiae [35]. Additional cysteine peptidase DUBs from C78, C85 
and clan CP C97 families have been characterised in another study [26]. Analysis of DUBs 
in promastigote lysates using the Cy5UbPRG ABP probe identified 6 active DUBs (DUB2, 
DUB15, DUB16, DUB17, DUB18 and DUB19) by mass spectrometry and additional active 
enzymes by in-gel fluorescence, demonstrating the presence of an active deubiquitinating 
system in L. mexicana. Additional active DUBs were identified by in-gel fluorescence 
comparison of wild type and gene deletion mutants (DUB6, DUB9), yet many remain 
unidentified and could be active below the limit of detection or possibly expressed in life 
cycle stages in the sandfly that were not examined in this study. We also used the ABP to 
demonstrate that many of the DUBs have activity that appears to remain constant in the 
different life cycle stages, yet we also demonstrated that ǻdub4, ǻdub7 and ǻdub13 had no 
detectable loss of fitness in the promastigote, but had a significant loss of fitness in the 
amastigote. This apparent contradiction might be explained by a specific requirement for 
stage-regulated DUB substrates. Intracellular amastigotes have a stringent metabolic 
response that is acutely sensitive to metabolic perturbation [36]. Our data indicate that 
amastigotes are also highly sensitive to disruption of ubiquitination homeostasis.  
The bar-seq screen and individual viability assay of DUB null mutants highlighted DUBs with 
potential roles in differentiation and infection. ǻdub4, ǻdub7 and ǻdub13 had the strongest 
loss of fitness defects observed in axenic amastigote, macrophage infection and mouse 
infection experiments. Additionally, ǻdub3, ǻdub5, ǻdub6, ǻdub8, ǻdub10, ǻdub11 and 
ǻdub14 showed strong loss of fitness uniquely during mouse infection, perhaps due to 
increased selective pressures inside the host or the longer duration of the experiment. 
Although we identified a number of life cycle defects using the bar-seq screen, there are 
some potential limitations to using a pooled library, as the fitness of individual null mutants 
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may be influenced by other mutants in the pool. This may explain, for example, the different 
phenotypes observed for ǻdub9 between the bar-seq experiment and viability assay/HASPB 
blot. Our individual profiling of axenic amastigote null mutants using the viability assay 
confirms the phenotypes we observed in the bar-seq screen, but further individual 
assessment on selected null mutant lines could be advantageous. The identification of 
several DUBs essential for differentiation was not unexpected as the Leishmania proteome 
differs substantially between promastigote and amastigote stages [37]. DUBs can control the 
abundance of Leishmania proteins by rescuing them from proteasomal degradation or, more 
indirectly, by regulating autophagy. Autophagy has been shown to be essential for the 
differentiation of promastigotes into amastigotes both in vitro and in vivo [33, 38]. Proteolysis 
is required for metacyclogenesis and the promastigote to amastigote transition [39] and an 
accumulation of ubiquitylated proteins in the cytosol has been documented at the onset of 
differentiation [40]. Therefore, a role for Leishmania DUBs in differentiation-associated 
protein degradation could explain the higher degree of essentiality observed for DUBs over 
other peptidases in our bar-seq screen.  
We were unable to generate null mutant lines for four DUBs, three C19 (DUB1, DUB2 and 
DUB12) and one C12 family (DUB16) peptidase. The successful generation of facilitated null 
mutant lines for the four DUBs provides a level of support that they are essential for the 
promastigote. DUB16 is related to human UCHL1 (33% identity) and UCHL3 (37% identity), 
for which one proposed role is the control of free ubiquitin levels through the processing of 
ubiquitin precursor and ubiquitinated proteins [41]. DUB16 could have a role in regulating 
free ubiquitin levels, something that must be further investigated. 
USP36 is the human DUB most closely related to DUB12 (28% identity) and has been 
shown to regulate the stability of nuclear proteins including c-Myc, B23 and fibrillarin, the 
latter two of which are required for rRNA processing and ribosomal biogenesis [42]. USP36 
deletion is lethal in mice, attributable to its role in rRNA processing and protein synthesis 
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[43]. However, deletion of the yeast homologue, Ubp10, only results in a reduced growth 
phenotype [44]. Further investigation must be performed to investigate if DUB12 shares any 
functional similarity with USP36 and to explain how DUB12 depletion caused cell death. 
Lastly, for the DUB12 overexpression line, we observed an increase in the activity of two 
forms of DUB12, likely arising from its proteolytic cleavage to 55 kDa proteins from an 85 
kDa precursor. The post-translational modification of DUBs is one way in which their activity 
has been shown to be regulated and, although rare, proteolytic cleavage of DUBs has been 
described for some human DUBs [45, 46]. 
DUB2 is a cysteine peptidase with a C19-UCH domain, a UBA domain at the C-terminus 
and a ZnF_UBP domain at the N-terminus. The most similar human DUBs are USP5 and 
USP13. USP5 is a well characterised member of the USP family responsible for the 
disassembly of the majority of unanchored poly-ubiquitin in vivo [47]. The ZnF-UBP domain 
of USP5 recognises the C-terminus of ubiquitin [48] and USP5 has been shown to hydrolyse 
Lys-63, Lys-48, Lys-11, Lys-29 linkages [49]. DUB2 is similar to USP5 in having broad 
linkage specificity towards all the di-ubiquitin chains except Met-1 and Lys-29 in vitro. Our in 
vitro experiments demonstrate that DUB2 exhibits deubiquitinating activity against both 
artificial DUB substrates (Cy5-Ub-PRG ABP and Ub-AMC) and di-ubiquitin. Several human 
DUBs have previously been demonstrated to have a pleiotropic function by regulating 
protein stability or by regulating assembly and function of different machineries. Similarly, 
the essentiality, localisation and interactome of DUB2 suggests a pleiotropic role in the 
deubiquitination of multiple substrates. The possibility that DUB2 is responsible for the 
release of ubiquitin from polyubiquitin chains could also explain the phenotype in Leishmania 
after DUB2 depletion. The sudden and significant depletion of free ubiquitin results in 
significant dysfunction of all molecular machinery associated with ubiquitin, such as 
proteasomal degradation, endocytosis, replication, transcription and RNA splicing. If this was 
the case, the parasite would enter a free ubiquitin crisis, which would eventually lead to 
death.  
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The interactome data suggest DUB2 plays a role in post-transcriptional gene regulation. In 
Leishmania and other kinetoplastids, gene expression occurs in an unusual manner 
involving constitutive polycistronic transcription and trans-splicing of a splice leader RNA to 
generate mature mRNAs [50]. Amongst the DUB2 interactors, one of the most strongly 
enriched proteins was cyclin 12 which in trypanosomes forms a tripartite complex with CRK9 
and a CRK9 associated protein, CRK9AP. The CYC12-CRK9-CRK9AP complex is essential 
for trans-splicing of the splice leader RNA [30]. However, CRK9 and CRK9AP were not 
detected in the DUB2 interactome, indicating that DUB2 plays a role in turnover of free 
CYC12. Depletion of CRK9AP causes a rapid loss of CYC12 at the protein but not mRNA 
level, suggesting dynamic regulation of CYC12 protein [30]. DUB2 may therefore protect 
free CYC12 from degradation. When DUB2 is absent, CYC12 may become a target for 
degradation, leading to co-depletion of CRK9 and a critical loss of trans splicing capacity. 
Alternatively, deubiquitination of CYC12 may be required for complex formation, similar to 
the requirement for the removal of ubiquitin from Bcl10 by Usp9x for its tripartite complexing 
to Malt1 and Carma1 [51]. Another strongly enriched protein in the DUB2 interactome was 
the histone chaperone NAP1, an important factor in nucleosome assembly [31]. This implies 
a role for DUB2 in nucleosome dynamics. In other eukaryotes, ubiquitination/de-
ubiquitination of H2A and H2B is a dynamic process that modulates the stability of 
nucleosomes to allow transcription/DNA replication to take place [52]. The transcription 
factors, splicing factors and DNA replication proteins co-enriched with DUB2 are consistent 
with a role in regulating nucleosome assembly/disassembly since this would place DUB2 in 
the vicinity of these processes. 
DUB activity can be regulated by post-translational modifications such as phosphorylation, 
for which one of the best characterised examples is activation of OTUD5/DUBA (OTU-
domain-containing protein 5) by phosphorylation in the catalytic domain [53]. Ubiquitination 
can also affect DUB activity, for example, ubiquitination of UCH-L1 near the active site 
prevents binding to ubiquitin [54]. We identified a phosphorylated region and a ubiquitination 
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site flanking the DUB2 UBA domain which could similarly regulate binding of DUB2 to 
ubiquitinated substrates. DUB2 has a broad specificity for diubiquitin cleavage, with Lys-27 
being the only linkage for which there is poor activity. Lys-11, Lys-29 and Lys-48 linked 
chains have roles in proteasomal degradation, Lys-29 is associated with lysosomal 
degradation and Lys-33 is involved in both secretory and endocytic pathways, acting as a 
sorting signal for membrane proteins [55]. Another preferred linkage of DUB2 is Lys-63 
which can serve as a molecular glue, allowing the rapid and reversible formation of pivotal 
signalling complexes. Lys-63 ubiquitin chains have been shown to regulate several 
biological processes including DNA repair, clearance of damaged mitochondria and protein 
sorting and they can guide assembly of large protein complexes that drive mRNA splicing 
and translation [55]. In the DUB2 pull down, the VPS4 protein was identified, which could 
indicate a putative role of DUB2 in endosome sorting and could explain why DUB2 cleaves 
Lys-33 and Lys-29. Whilst VPS4 is the only known protein associated with 
autophagy/endocytosis that was identified in the DUB2 interactome, a role in the endocytic 
system fits with DUB2 lysosomal localisation. Previously, VPS4 was shown to play a role in 
endosome sorting and autophagy in L. major, which are essential for the differentiation and 
virulence of this parasite [33].  
In the past decade there has been an expanding interest in DUBs as potential drug targets 
as they have been shown to play a crucial role in both cancer and neurodegenerative 
diseases [56]. The determination of the structure of multiple DUBs, including catalytic 
domains, in combination with the development of advanced high-throughput screening-
compatible assays with USP substrates has resulted in the discovery of several inhibitors 
against a select number of human DUBs including USP7 [57, 58] and USP14 [59]. DUB2 is 
the first DUB to have been genetically validated as a drug target in L. mexicana. DiCre 
permitted the analysis of emerging phenotypes, confirming the essential role for DUB2 in 
promastigotes and in the establishment of mouse infection. Analysing Leishmania genes in 
this manner represents a high level of genetic validation [60]. To date, most drug target 
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validation has relied on genetic manipulation of promastigotes, however, the bar-seq 
approach presented here has revealed some DUBs to have amastigote-specific loss of 
fitness, making DUBs 3, 5, 6, 8, 10, 11 and 14 potential drug targets. As DUB6 is related to 
human USP7 and DUB14 to human USP14, chemical tools developed for human DUB drug 
discovery programs [59] may be useful chemical entry points to develop inhibitors to the 
Leishmania enzymes. 
 
Materials and Methods 
Ethics Statement 
All experiments were conducted according to the Animals (Scientific Procedures) Act of 
1986, United Kingdom, and had approval from the University of York Animal Welfare and 
Ethical Review Body (AWERB) committee. 
 
 
Culture of Leishmania  
Leishmania mexicana (MNYC/BZ/62/M379) were grown in HOMEM (Gibco) supplemented 
with 10% (v/v) heat-inactivated foetal calf serum (HIFCS) (Gibco) and 1% (v/v) 
Penicillin/Streptomycin solution (Sigma-Aldrich) at 25o C. Mid-log phase parasites were 
defined as between 4-8 x 106 cells mL-1 and stationary phase parasites between 1.5-2.5 x 
107 cells mL-1.  
 
L. mexicana promastigotes were differentiated to axenic amastigotes as previously 
described [61]. Briefly, stationary phase culture of L. mexicana was pelleted by 
centrifugation at 1,000 x g for 10 minutes and washed with 1 x PBS. Cells were then 
resuspended in amastigote culture medium (Schneiders Drosophila medium [Gibco], 20% 
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HIFCS and 0.015 mg mL-1 hemin [stock dissolved in 50 mM NaOH], pH 5.5) with a 
concentration of 2 x 106 cells mL-1 in 6-well plates. Except where stated otherwise, cells were 
then incubated at 32°C with 5% CO2. For transformation of amastigotes back to 
promastigotes after 120 h, 100 ȝL of axenic amastigotes were diluted in 5 mL of HOMEM 
medium with 10% HIFCS and 1% Penicillin/Streptomycin and placed in 6-well plates. The 
plate was then incubated at 25°C. Transgenic parasites were grown with the following 
antibiotic concentrations: G418 (Neomycin) at 50 ȝg mL-1; Hygromycin at 50 ȝg mL-1; 
Blasticidin S at 10 ȝg mL-1; Puromycin at 30 ȝg mL-1 (antibiotics from InvivoGen). To assess 
viability assay of axenic amastigotes, 200 ȝL of axenic amastigotes at 1 x 106 cells mL-1 
were placed in 96 well plates and incubated at 35°C with 5% CO2. 20 ȝL of 0.05 ȝM 
resazurin (Sigma) was added and the plate was incubated overnight as before. The next 
day, resorufin fluorescence (579 Ex/584 Em) was measured using a Polarstar plate reader 
(Omega).  
 
To assess infection of mice, 106 stationary phase L. mexicana promastigotes were injected 
into the right footpad of female BALB/c mice (Charles River Laboratories). Lesion size was 
monitored weekly. Parasite burden was assessed as previously described [62]. For profiling 
of DUBs in lesion-derived amastigotes, 4 x 106 stationary phase L. mexicana were injected 
into the rump of female BALB/c mice. Lesion size was monitored weekly. For the purification 
of lesion derived amastigotes the lesion tissue was collected in amastigote stabilisation 
buffer (PSGEMKA) [63] cut into pieces and passed through a sterile 100 µm cell strainer 
(BD) to disrupt the host macrophages and liberate the amastigotes. The suspension was 
incubated with 125 mg L-1 saponin for 5 mins, centrifuged 2,000 x g for 10 mins and the 
pellet was washed twice with PSGEMKA buffer. Cell debris was eliminated by passage 
through a glass wool - Sephadex CM-25 column. The suspension obtained was centrifuged 
at 2,000 x g for 10 mins. Thereafter, the supernatants were discarded, and the pellets were 
resuspended in Schneiders Drosophila medium supplemented as indicated above.  
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L. mexicana transfections were performed using a T Cell Nucleofector Kit (Lonza) as 
described previously [26]. The transfected culture was split between two flasks to select for 
independent transfection events and incubated overnight at 25°C to recover. The next day, 
suitable antibiotics were added and cells cloned by serial dilutions of 1 in 6, 1 in 66 and 1 in 
726 in 96-well microplates. 
 
Phylogenetic Analysis 
The protein sequences for DUBs were extracted from (Uniprot- https://www.uniprot.org/) 
[64].  For human DUBs the canonical sequence was used as it was determined by Uniprot. 
The protein alignment was performed using MUSCLE (multiple sequence alignment with 
high accuracy and high throughput). A constraint tree was created by including DUBs into 
the seven known families and a phylogenetic tree was generated by RAxML (https://raxml-
ng.vital-it.ch/#/) [65]. The LG Substitution matrix was used. The best fit model tree was 
further designed initially in the iTOL INTERACTIVE TREE OF LIFE (https://itol.embl.de/) 
where branch length was ignored, and an unrooted tree style was formed. Finally, Adobe 
Illustrator was then used to finalise the tree. 
 
Life cycle phenotyping using bar-seq 
Null mutants were generated using a CRISPR-Cas9-based approach [23] with a cell line 
expressing Cas9 and T7 RNA polymerase [26]. DNA was harvested from clones or 
populations for diagnostic PCRs using the QIAGEN DNeasy Blood and Tissue Kit. Two sets 
of primers were designed to confirm the generation of null mutants, the first specific to the 
ORF of the target gene and the second specific to the UTRs (forward primer 5-UTR, reverse 
primer 3-UTR).  
 
Null mutant lines were grown to mid-log phase, spun down at 1,000 x g for 10 min and 
pooled in equal proportions in Graces medium (Graces insect media [Sigma-Aldrich] with 
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4.2 mM NaHCO3, 10% FCS [Gibco], 1 x Penicillin/Streptomycin [Gibco] and 1 x BME 
Vitamins [Sigma-Aldrich] and adjusted to pH 5.25) up to a total concentration of 2 x 106 cells 
mL-1. Cultures were prepared in sextuplicate to provide technical replication. Next, the 
pooled cells were grown at 25°C for 7 d to allow for the enrichment of metacyclic 
promastigotes. To prepare axenic amastigotes, promastigotes from the 168 h time point 
were centrifuged and resuspended in amastigote medium at 2 x 106 cells per well. Cells 
were then cultured at 35°C with 5% CO2.  
 
Bone marrow-derived macrophages were extracted from female BALB/C mouse femur, 
equilibrated in warm DMEM (GE Life Sciences), spun at 200 x g for 10 min and 
resuspended in macrophage medium (DMEM [Invitrogen] plus 10% FCS and 2 mM L-
glutamine) in order to have 2.5 x 106 cells per well [66]. Enriched metacyclic cells were 
purified using a Ficoll 400 (Sigma-Aldrich) gradient (40%, 10% and 5% Ficoll) and 
centrifuged at 1,300 x g for 10 min. Following washing with Graces medium, metacyclic 
promastigotes were added to the macrophages in a 1:1 ratio and left to interact for 4 h at 
35°C with 5 % CO2. Excess Leishmania cells were then removed by washing with DMEM 
and the cells incubated in DMEM 10% HIFCS for 12 h and 72 h. 
 
To perform the mouse infections, 106 purified metacyclic promastigotes were injected into 
the left footpad of BALB/c mice. Mice were culled at 3 and 6 weeks post-inoculation. At the 
relevant time points, DNA was extracted from experimental samples and processed using 
the QIAGEN DNeasy Blood and Tissue Kit. DNA samples were prepared for next-generation 
sequencing by first amplifying unique barcodes by PCR using the following primers: 5-
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAgatgatgattacTAATACGACTCACTATA
AAACTGGAAG-3 and 5-
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAGAGACAGGCATGCCTT-3 
containing the Illumina adapter sequence. Reactions were set up with Q5 polymerase (NEB) 
as per the manufacturers instructions except for the following changes: just 0.5 x of Q5 
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Reaction Buffer and Q5 High GC Enhancer were used. The cycling conditions were 98°C for 
5 min followed by 20-25 cycles of 98°C for 30 sec, 60°C for 30 sec and 72°C for 10 sec. 
Following purification of the PCR reactions using the QIAGEN MinElute PCR Purification Kit, 
a second PCR was performed using Illumina's Nextera XT indexing primers in order to add 
unique barcode sequences to each sample. 8 cycles of PCR amplification were performed 
using NEBNext Q5 Polymerase 2X Master Mix (New England Biolabs), according to the 
manufacturers guidelines. Indexed amplicons were purified using 0.9 X AMPure XP beads 
(Beckmann Coulter) and eluted into low TE buffer before quantitation and pooling at 
approximately equimolar ratios. Amplicon pools were then sent for 150 base paired end 
sequencing on an Illumina HiSeq 3000 sequencer at the University of Leeds Next 
Generation Sequencing Facility. 
 
Illumina read sequences were analysed using a custom Python script to search for the 12 bp 
sequence preceding the barcode. If an exact match was found, the following 12 bp 
sequence was counted as a barcode sequence. A total count for each unique barcode 
sequence was generated for each sample. Next, the relative fitness of null mutants at each 
life cycle stage was calculated by taking the number of unique barcode reads for each null 
mutant line and dividing it by the total number of expected barcode reads. Significant 
increases or decreases in null mutant line fitness between adjacent samples in the 
experimental workflow were analysed using unpaired t-tests and the Holm- ídák method in 
GraphPad Prism 7.  
 
Construction of plasmids 
A full list and descriptions of all primers and plasmids used in this study can be found in 
Table S3. The construction of the plasmids needed for the generation of DUB2 inducible 
gene deletion was performed as previously described [29]. The DUB2 gene including stop 
codon was cloned into pGL2315, creating pGL2727. For the complementation plasmids, 
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pNUS-DUB1, DUB2, DUB12 and DUB16 expression plasmids were generated using Gibson 
Assembly. The successful clones were confirmed using PCR and sequencing.  
 
Induction of diCre mediated gene deletion  
A modified version of the DiCre inducible system [29] was used. Two dimerisable Cre 
recombinase subunits were integrated into the ribosomal locus. DiCre in cell lines containing 
both diCre and loxP flanked genes of interest was induced by the addition of between 100 
nM and 1 ȝM rapamycin (Abcam). Promastigotes were then allowed to grow for 48 h and 
split into new cultures with a concentration of 1 x 105 cells mL-1 and induced again with 100 
nM of rapamycin.  
 
Viability analyses 
2-5 x 106 L. mexicana promastigotes were pelleted by centrifugation at 1,000 x g for 10 mins 
and washed twice with PBS with 5mM of EDTA. Cells were resuspended in 1mL of PBS with 
5mM EDTA and 1µg mL-1 of propidium iodide (PI) and 1 µg mL-1 of RNAse A. Cell 
fluorescence was analysed on a Beckman Coulter, CyAn ADP. Data were analysed on 
FlowJo software (Tree Star Inc.).  
 
Preparation of protein extracts  
3 x 107 L. mexicana cells in the desired life cycle stage were pelleted by centrifugation at 
1,000 g for 10 min. Cells were washed in 1 x PBS and lysed by resuspending in 40 ȝL of 1 x 
SDS-PAGE loading buffer. Next, samples were heated for 10 minutes at 90°C on a heat 
block. Samples were allowed to cool down at room temperature and 250 U of Expedeon 
BaseMuncher endonuclease was added to each sample. Samples were then incubated at 
37oC for 30 minutes and loaded directly into a NuPAGE 4-12% Bis-Tris protein gel 
(Thermofisher) or stored at -20o C.  
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Cy5UbPRG profiling  
3 x 107 cells from a log-phase L. mexicana culture or 9 x 107 amastigote were spun at 1,000 
x g and washed three times with 1 mL of ice-cold TSB Wash buffer (44 mM NaCl, 5 mM KCl, 
3 mM NaH2PO4, 118 mM sucrose and 10 mM glucose, pH 7.4). Next, the cells were lysed 
using a newly prepared ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 120 mM NaCl, 1% 
NP40 and freshly added in order: 1 ȝg mL-1 pepstatin, 1 x cOmplete ULTRA Tablets, [Mini, 
EASYpack Protease Inhibitor Cocktail, Roche], 1 mM DTT, 1 mM PMSF, 0.01 mM E64). 
Samples were incubated at 4°C for 15 minutes. Afterwards, samples were centrifuged at 
17,000 x g for 15 minutes and the supernatant withdrawn. Samples were prepared to have a 
protein concentration of 1 mg mL-1 in a total volume of 25 ȝL. 2 ȝL of 50 mM NaOH and 1 
ȝM of Cy5UbPRG (UbiQ) were added. Lysis buffer was used to top up to a final volume of 
25 ȝL. The reaction was then incubated at room temperature for 30 min and stopped by the 
addition of 3 x loading dye. 12 ȝL were then analysed in a gradient 4-12% NuPage Bis-Tris 
protein gel, for exactly 90 min at 200 V. The gel was then washed with water and imaged 
with Amersham Typhoon with Excitation: 635 nm, Filter: Cy5 670BP30 (GE Healthcare Life 
Sciences).  
 
For purification of DUBs cyanogen bromide (CNBr)-activated Sepharose 4B resin (GE 
Healthcare) was used to couple with Ub-PRG (1.2 pmol) or Ubiquitin (1.2 pmol) according to 
the manufacturers protocol (GE Healthcare). Beads were then stored in 4°C until used. 50 
mg of the coupled resin of either Ub-PRG or ubiquitin were incubated with fresh Leishmania 
lysate collected from 1 x108 cells (prepared as described above) at 37°C for 3 h. The beads 
were then washed with PBS plus 1% Triton X-100 (3 x 10 mL), 2% CHAPS, 8 M Urea in 
PBS and distilled water. The bound proteins were then digested on-bead with trypsin and 
analysed by MS/MS spectrometry. The MS data was processed using Data Analysis 
software (Bruker) and the automated Matrix Science Mascot Daemon server (v2.4.1). 
Protein identifications were assigned using the Mascot search engine to interrogate protein 
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sequences in the annotated proteins database (obtained from TriTrypDB), allowing a mass 
tolerance of 0.4 Da for both MS and MS/MS analyses.  
 
Immunoprecipitation of myc-tagged Leishmania proteins 
For each of a total of 3 independent replicates, 1 x 109 parasites were washed twice in PBS 
and cross-linked with 1 mM dithiobis(succinimidyl propionate) (DSP, Thermo Scientific) in 10 
ml PBS for 10 min at 26°C. DSP was quenched with 20 mM Tris pH 7.5 for 5 min. Parasites 
were lysed in ice cold 500 ȝl lysis buffer (1% NP40, 50 mM Tris pH 7.5, 250 mM NaCl, 1 mM 
EDTA, 0.1 mM PMSF, 1 ȝg mL-1 pepstatin A, 1 ȝM E64, 0.4 mM 1-10 phenanthroline, 20 ȝl 
mL-1 proteoloc (Expedeon), 0.17 complete protease inhibitor tablets mL-1 (Sigma)) by probe 
sonication for 3 × 5 sec. Lysate was centrifuged for 10 min at 10,000 x g at 4°C and protein 
concentration in the supernatant measured by BCA assay (Thermo scientific). Lysate 
equivalent to 5 mg of total protein was incubated with 30 ȝl anti-myc magnetic beads 
(Thermo scientific) for 2.5 hr at 4°C with rotation. Beads were washed 4 × 300 ȝl ice cold 
lysis buffer for 5 min each wash followed by two PBS washes. Beads were then stored at -
80°C. Myc-tagged protein was eluted at room temperature with 25 ȝl myc-peptide (0.5 
mgmL-1 in PBS, Sigma) for 15 minutes at 700 rpm mixing. The elution step was repeated 
and eluates pooled. 1/10th of the elution was used to check successful immunoprecipitation 
by western blot. The remainder was mixed with 4 volumes of absolute methanol and 1 
volume of chloroform and vortexed for 1 min. The sample was then centrifuged for 1 h at 
18,000 x g at 4°C. The pellet was washed with 270 ȝL of absolute methanol and centrifuged 
for 10 min at 18,000 x g at room temperature. The pellet was resuspended in 150 ȝL 50 mM 
TEAB pH 8.5, 0.1% PPS silent surfactant (Expedeon) for 1 h by shaking at 800 rpm at room 
temperature. Afterwards, 10 mM of Tris (2-carboxyethyl) phosphine (TCEP) and 10 mM 
Iodoacetamide (IAA) were added to the sample and incubated for 30 min at room 
temperature in the dark. Finally, 200 ng of trypsin and 1 mM CaCl2 were added and proteins 
digested overnight at 37°C 200 rpm. After digestion, PPS silent surfactant was cleaved by 
acidifying the digest to 0.5% trifluoroacetic acid (TFA) and incubating 1 h at RT. Digest was 
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centrifuged for 10 min at 17,000 x g. Peptides were desalted with C18 (3M Empore) 
desalting tips. 
 
Samples were loaded onto an UltiMate 3000 RSLCnano HPLC system (Thermo) equipped 
with a PepMap 100 Å C18, 5 µm trap column (300 µm x 5 mm Thermo) and a PepMap, 2 
µm, 100 Å, C18 EasyNano nanocapillary column (75 ȝm x 150 mm, Thermo). The trap wash 
solvent was aqueous 0.05% (v:v) trifluoroacetic acid and the trapping flow rate was 15 µL 
min-1. The trap was washed for 3 min before switching flow to the capillary column.  
Separation used gradient elution of two solvents: solvent A, aqueous 1% (v:v) formic acid; 
solvent B, aqueous 80% (v:v) acetonitrile containing 1% (v:v) formic acid. The flow rate for 
the capillary column was 300 nL min-1 and the column temperature was 40°C. The linear 
multi-step gradient profile was: 3-10% B over 7 min, 10-35% B over 30 min, 35-99% B over 
5 min and then proceeding to wash with 99% solvent B for 4 min. The column was returned 
to initial conditions and re-equilibrated for 15 min before subsequent injections. Each 
independent replicate was injected once. 
The nanoLC system was interfaced with an Orbitrap Fusion Tribrid mass spectrometer 
(Thermo) with an EasyNano ionisation source (Thermo). Positive ESI-MS and MS2 spectra 
were acquired using Xcalibur software (version 4.0, Thermo). Instrument source settings 
were: ion spray voltage, 1,900 V; sweep gas, 0 Arb; ion transfer tube temperature; 275°C. 
MS1 spectra were acquired in the Orbitrap with: 120,000 resolution, scan range: m/z 375-
1,500; AGC target, 4e5; max fill time, 100 ms. Data dependent acquisition was performed in 
top speed mode using a 1 sec cycle, selecting the most intense precursors with charge 
states >1.  Easy-IC was used for internal calibration. Dynamic exclusion was performed for 
50 sec post precursor selection and a minimum threshold for fragmentation was set at 5e3. 
MS2 spectra were acquired in the linear ion trap with: scan rate, turbo; quadrupole isolation, 
1.6 m/z; activation type, HCD; activation energy: 32%; AGC target, 5e3; first mass, 110 m/z; 
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max fill time, 100 msec.  Acquisitions were arranged by Xcalibur to inject ions for all 
available parallelisable time. 
Peak lists in .raw format were imported into Progenesis QI (Version 2.2., Waters) and LC-
MS chromatograms aligned.  Precursor ion intensities were normalised against total intensity 
for each acquisition. A combined peak list was exported in .mgf format for database 
searching against the L. mexicana subset of the TriTrypDB database (8,250 sequences; 
5,180,224 residues). Mascot Daemon (version 2.6.1, Matrix Science) was used to submit the 
search to a locally-running copy of the Mascot program (Matrix Science Ltd., version 2.6.1).  
Search criteria specified: Enzyme, trypsin; Max missed cleavages, 2; Fixed modifications, 
Carbamidomethyl (C); Variable modifications, Oxidation (M), Phosphorylation (S,T,Y); 
Peptide tolerance, 3 ppm; MS/MS tolerance, 0.5 Da; Instrument, ESI-TRAP. Peptide 
identifications were passed through the percolator algorithm to achieve a 1% false discovery 
rate as assessed against a reversed database and individual matches further filtered to 
minimum expect scores of 0.05. The Mascot .XML result file was imported into Progenesis 
QI and peptide identifications associated with precursor peak areas. Relative protein 
abundance was calculated using precursor ion areas from non-conflicting unique peptides.  
Accepted protein quantifications were required to contain a minimum of two unique peptide 
matches. Interactors were scored using SAINTq [67], using a false discovery rate threshold 
of <1% to select high confidence DUB2 interactors. Complete mass spectrometry data sets 
are available to download from MassIVE (MSV000085242) and ProteomeXchange 
(PXD018415). The doi for the data is [doi:10.25345/C5Z10J]. 
 
Protein expression and purification 
A baculovirus expression system was used for the expression of DUB2 recombinant protein 
in sf9 insect cells as described in the Bac-to-Bac Baculovirus Expression protocol 
(Invitrogen). The gene was first cloned into the PFastBacNKI-his-3C-LIC vector using 
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Ligation Independent Cloning (LIC). After three days, the insect cells were lysed in lysis 
buffer (30 mM Tris-HCl, pH 8, 0.3 M NaCl, 0.03 M imidazole, 5 mM ȕ-mercaptoethanol and 1 
tablet of cOmplete ULTRA Tablets, Mini, EASYpack Protease Inhibitor Cocktail, Roche) by 
sonication. The samples were then centrifuged (21 K, 4°C, 30 min) and the supernatant 
applied to an AKTA Start (GE Life Sciences) at 5 mL min-1, to a 5 mL His- trap crude FF 
column (GE Life Sciences).  This was washed with Buffer A (30 mM Tris-HCl pH. 8, 0.3 M 
NaCl, 0.03 M imidazole, 5 mM ȕ-mercaptoethanol) and the protein eluted with increasing 
concentration of imidazole (0.03-0.5 M). Protein was concentrated using Amicon Ultra-4 30k 
MWCO (Millipore). 3C protease was added to purified protein in a 1:50 (w:w, 
3C:Recombinant protein) ratio with 2 mM DTT. The aliquot was added to a 16 kDa dialysis 
tube and incubated at 4°C in buffer A overnight. Protein was loaded onto a 5 mL His-trap 
crude FF column and ran as described above. The flow-through from the His-tag cleavage 
containing the tag free protein was concentrated to 2 mL using Amicon Ultra-4 30k MWCO 
(Millipore). The concentrated protein was applied to a HiLoad 16/600 S75pg column (GE Life 
Sciences), equilibrated and eluted in 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM ȕ-
mercaptoethanol. Fractions containing the protein were identified by absorbance at 280 nm 
and analysed by 10% SDS-PAGE. These fractions were pooled and concentrated up to 2 
mg mL-1. 1 mM of DTT was added to the sample and the protein stored at -80°C. 
 
Ubiquitin Probe Assay for Recombinant protein  
10 ȝL of the appropriate concentration of the recombinant DUB was incubated with 2 ȝL 50 
mM NaOH, 5 ȝL dH2O and 2 ȝL 0.25 ȝg mL-1 ubiquitin probe Cy5UbPRG (UbiQ) for 30 min 
at room temperature. Binding of probe was analysed using a NUPAGE 4-12% Bis-Tris Gel. 
The gel was then scanned using the Amersham Typhoon (GE Healthcare Life Sciences) and 
stained with InstantBlue Protein Stain.  
 
The in vitro enzymatic assay with the fluorogenic substrate ubiquitin-7-amido-4- 
methylcoumarin (Ub-AMC, UbiQ) was assembled in a 384-well microplate (Thermo 
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Scientific). Assays were performed in 20 ȝL reaction volumes and in triplicate. The reactions 
were initiated by the addition of 10 ȝL of substrate or enzyme. Substrate and enzymes were 
diluted in buffer containing 50 nM Tris, pH 8.0, 0.15 M NaCl, 5 nM DTT and 0.05% CHAPS. 
The fluorescence intensity was monitored with a Polarstar plate reader (Omega) equilibrated 
at 25°C at intervals of 20 sec for 20 min using excitation/emission filter pairs of 340/460 nm. 
The fluorescence value was then converted into concentration using a standard curve. The 
standard curve was determined by allowing the reactions to plateau and the maximum 
arbitrary fluorescence units were measured and plotted against a known substrate 
concentration. An AMC concentration against time graph was generated in Excel software 
and the initial slope of each reaction was determined by generating a linear regression. For 
the determination of the Km and kcat values of DUB2, the enzyme concentrations were kept 
constant, and the concentration of Ub-AMC varied from 0.25 ȝM to 32 ȝM. The initial rates in 
ȝM sec -1 were then plotted against substrate concentration (ȝM) in Prism 7 software. The 
data were fitted to the Michaelis-Menton equation so the kinetic parameters, Km and kcat 
were determined.  
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Supplementary Data: 
S1 Fig.  Protein sequence alignment of Leishmania DUBs. Multiple protein sequence 
alignment of Leishmania DUBs and selected reference human DUB sequences showing 
their active residues. Human DUB sequences were obtained from UniProtKB: PAN2 
(Q504Q3), USP7 (Q93009), USP8 (P40818), BAP1 (Q92560), UCHL1 (P09936), UCHL3 
(P15374), UCHL5 (Q9Y5K5), OTUB1 (Q96FW1), OTUB2 (Q96DC9) and OTULIN 
(Q96BN8). C19, C12 and C65 DUB families were aligned using the T-Coffee multiple 
sequence alignment program.  A yellow star represents the active cysteine and the blue star 
represents the active histidine.  
 
S2 Fig Generation of the DUB null mutant library. Diagnostic PCRs were performed to 
check the successful generation of null and facilitated null mutants. PCR analysis of 
genomic DNA of at least two individual clones (null mutants, CL1, CL2 etc) or two separate 
populations (facilitated null mutants), using the indicated set of primers: ORF-specific 
primers (A), UTR-specific primers (B) or ORF-specific, 5-UTR-blasticidin or UTR-specific 
primers 9C). As a control, the parental Cas9 T7 cell line was used. The resulting amplicons 
were resolved on a 1% agarose gel and stained with SYBR safe. The expected size of the 
resulting amplicons is presented in Table S3.  A schematic representation of the wild type, 
heterozygous, null mutant and facilitated null mutant genomic loci including the diagnostic 
primers (green arrows primers bind to ORF, grey arrow primers bind to UTRs and amplify 
across the loci, purple arrow binds to the blasticidin resistance marker) is also shown in (C). 
 
S3 Fig. Activity profiling of the DUB null mutant cell lines.  
(A) Lysate extracted from log-phase L. mexicana promastigotes treated with or without 
Cy5UbPRG for 30 min. Proteins were separated by SDS-PAGE and in-gel fluorescence 
(Cy5) was captured using a Typhoon imager followed by Coomassie staining as a loading 
control. (B) Lysates extracted from null mutant lines of log-phase L. mexicana promastigotes 
treated with Cy5UbPRG for 30 min. In-gel fluorescence images were obtained as for (A). 
14 
 
The red arrowhead shows the position where an active DUB is missing compared to the 
parental T7 Cas9 cell line. (C) Western blot analysis of 2 x 107 axenic amastigotes. Samples 
were separated in a 4-15% protein gel. The stain-free gel used contains trihalo compounds 
which, in the presence of the UV-light, react with tryptophan residues, producing 
fluorescence. The gel was activated by 45 sec UV exposure, proteins were transferred to a 
PVDF membrane and probed with 1:1,500 dilution of anti-HASPB. Finally, as a loading 
control the total protein was determined using the stain-free property of the gel. (D) Lysate 
extracted from differentiated promastigotes to axenic amastigotes (48 h and 144 h after 
initiation of axenic differentiation) treated with or without Cy5UbPRG for 30 min. Protein was 
separated in an SDS-PAGE gel, and the image was captured using a Typhoon imager and 
the gel stained with Coomassie.  
 
S4 Fig. Localisation of endogenously tagged DUB2. Live cell imaging of L. mexicana 
procyclic promastigotes expressing mNeonGreen (mNG) tagged DUB2. DNA is stained with 
Hoechst 33342 and a representative selection of images is shown. DIC, differential 
interference contrast. 
 
S5 Fig. Generation and validation of DUB2 inducible cell line. (A) Left: PCR analysis of 
extracted gDNA demonstrates successful integration of HYG cassette. The replacement of 
DUB2 wild type allele with the HYG cassette was detected by PCR amplification using the 
primers shown in the schematic (right). The forward primer was designed to bind to the ORF 
of DUB2 whereas the reverse primer binds on the 3 UTR of the target gene. Black arrows 
represent the primers. (B) PCR amplification of DUB2-/+FLOX Clone 4, 6, DUB2-/+FLOX [DUB2] 
and DUB2-/+FLOX [DUB2C312A] surviving parasites after treatment with RAP in the clonal assay 
(Fig 4E). Schematic representation of the primers used for the PCR as well as the expected 
fragments are shown in Fig 4A. (C) Compiled flow cytometry results of live/dead cells 
detected using propidium iodide staining in DUB2+/+flox and DUB2-/+flox promastigotes over the 
course of 96 hours post induction. Cells were grown for 48 hours with or without rapamycin. 
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Afterwards, the cells were seeded at a density of 1ௗ×ௗ105 cells mLí1 and allowed to grow in 
the presence or absence of 100 nM of RAP. Samples were collected every 24 h. Flow 
cytometry was used to analyse the samples. The data were then collected and analysed 
with FlowJo_v10 software, where the percentage of dead cells was determined. The data 
were analysed in Prism software and an unpaired t-test performed to indicate significance 
(n=3) between different time points, comparing treated with RAP to untreated samples. Error 
bars indicate the standard deviation of a mean. ***p < 0.001, ****p < 0.0001. 
S6 Fig. DUB2 Immunoprecipitation using anti-myc beads. (A) DUB profiling using the 
ABP Cy5UbPRG. Cell extract from a WT and mNeon:DUB2 was incubated with Cy5UbPRG 
for 30 min. Proteins were then separated by SDS-PAGE and imaged. The yellow arrow 
represents the DUB2 WT band whereas the red arrow represents the mNeon-DUB2. (B) 
Western blotting analysis with anti-myc antibody (1:2,000) of protein cell extract from 
samples collected after immunoprecipitation of control cell line (WT) and mNeon:DUB2. E1, 
E2 were samples collected from the elution (myc peptide 0.5 mg mL෥ in PBS). 
 
S7 Fig. Purification of DUB2 active (left) and DUB2C256 inactive protein (right). (A) 
Protein gel of the soluble fraction (L), flow though (FT) and eluted fractions across the peak 
that were collected after Ni2+ affinity chromatography. 10 ȝL of the protein samples were 
separated by SDS-PAGE and visualised by InstantBlue Protein Stain. (B) Protein gel of the 
sample before overnight dialysis with protease 3C for the removal of the his-tag (T), after 
overnight dialysis (U) and flow through and eluted fractions across the peaks collected after 
the second Ni2+ affinity chromatography. (C) Protein gel of the diluted (Di) and concentrated 
(Co) samples before application to a HiLoad 16/600 S75pg column and eluted fractions 
collected after size-exclusion chromatography.  
 
S1 Table. Leishmania mexicana C12, C19 and C65 deubiquitinases. 
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S2 Table. Proteins specifically affinity-enriched with Cy5UbPRG. 
 
S3 Table. Oligonucleotide primers. 
 
S4 Table.  Bar-seq data. 
 
S5 Table.  DUB2 interacting partner data. 
 
S6 Table. DUB2 ubiquitination and phosphorylation sites. 
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